See the DrugPatentWatch profile for cosentyx

The need for Cosentyx (secukinumab) dosage increases is determined by several factors, primarily the patient's response to treatment and the presence of certain conditions.

Firstly, if a patient does not achieve the desired therapeutic response with the initial Cosentyx dosage, a dosage increase may be considered. This is often determined through regular monitoring of the patient's symptoms and disease activity. For instance, in patients with psoriasis, the Psoriasis Area and Severity Index (PASI) score is a common measure used to assess treatment response [1].

Secondly, in patients with certain conditions, a higher dosage of Cosentyx may be required. For example, in patients with active psoriatic arthritis or ankylosing spondylitis, a higher dosage may be prescribed to achieve optimal clinical outcomes [2].

It's important to note that dosage increases should be carefully considered and managed under the guidance of a healthcare professional. This is because higher dosages can increase the risk of side effects and may not necessarily lead to improved efficacy in all cases.

In terms of drug patents, according to DrugPatentWatch.com, Cosentyx is currently under patent protection in the United States until 2025 [3]. This means that generic versions of the drug are not yet available, and the cost of treatment may be a factor in determining the need for dosage increases.

In summary, the need for Cosentyx dosage increases is determined by the patient's response to treatment, the presence of certain conditions, and under the guidance of a healthcare professional. The current patent status of Cosentyx may also impact dosage decisions.

Sources:
[1] National Psoriasis Foundation. (2021). Psoriasis Area and Severity Index (PASI). https://www.psoriasis.org/about-psoriasis/treatments/psoriasis-area-and-severity-index-pasi
[2] Novartis. (2021). Cosentyx (secukinumab). https://www.novartis.com/sites/www.novartis.com/files/cosentyx.pdf
[3] DrugPatentWatch.com. (2021). Cosentyx (secukinumab). https://www.drugpatentwatch.com/drugs/cosentyx-secukinumab/